Ocular Therapeutix, Inc. (OCUL)
OCUL Stock Price Chart
Explore Ocular Therapeutix, Inc. interactive price chart. Choose custom timeframes to analyze OCUL price movements and trends.
OCUL Company Profile
Discover essential business fundamentals and corporate details for Ocular Therapeutix, Inc. (OCUL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jul 2014
Employees
274.00
Website
https://www.ocutx.comCEO
Pravin U. Dugel
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL Financial Timeline
Browse a chronological timeline of Ocular Therapeutix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.38.
Earnings released on 5 Aug 2025
EPS came in at -$0.39 falling short of the estimated -$0.35 by -11.43%, while revenue for the quarter reached $13.46M , missing expectations by -6.48%.
Earnings released on 5 May 2025
EPS came in at -$0.37 falling short of the estimated -$0.29 by -27.59%, while revenue for the quarter reached $10.63M , missing expectations by -18.80%.
Earnings released on 3 Mar 2025
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%, while revenue for the quarter reached $17.08M , missing expectations by -0.17%.
Earnings released on 14 Nov 2024
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%, while revenue for the quarter reached $15.43M , missing expectations by -8.68%.
Earnings released on 7 Aug 2024
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%, while revenue for the quarter reached $16.44M , beating expectations by +3.93%.
Earnings released on 7 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.18 by -33.33%, while revenue for the quarter reached $14.72M , missing expectations by -4.51%.
Earnings released on 11 Mar 2024
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $14.80M , missing expectations by -5.78%.
Earnings released on 7 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.27 by -88.89%, while revenue for the quarter reached $14.95M , missing expectations by -5.80%.
Earnings released on 7 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%, while revenue for the quarter reached $15.19M , beating expectations by +3.66%.
Earnings released on 8 May 2023
EPS came in at -$0.31 falling short of the estimated -$0.27 by -14.81%, while revenue for the quarter reached $13.37M , missing expectations by -5.15%.
Earnings released on 6 Mar 2023
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $14.08M , beating expectations by +4.01%.
Earnings released on 7 Nov 2022
EPS came in at -$0.30 falling short of the estimated -$0.23 by -30.43%, while revenue for the quarter reached $11.97M , missing expectations by -16.16%.
Earnings released on 8 Aug 2022
EPS came in at -$0.28 falling short of the estimated -$0.23 by -21.74%, while revenue for the quarter reached $12.27M , missing expectations by -13.91%.
Earnings released on 9 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $13.19M , missing expectations by -5.52%.
Earnings released on 28 Feb 2022
EPS came in at -$0.23 matching the estimated -$0.23, while revenue for the quarter reached $12.31M , missing expectations by -11.71%.
Earnings released on 8 Nov 2021
EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%, while revenue for the quarter reached $12.15M , missing expectations by -12.44%.
Earnings released on 9 Aug 2021
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%, while revenue for the quarter reached $11.72M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.24 falling short of the estimated -$0.20 by -20.00%, while revenue for the quarter reached $7.34M , missing expectations by -24.77%.
Earnings released on 11 Mar 2021
EPS came in at -$0.23 falling short of the estimated -$0.18 by -27.78%, while revenue for the quarter reached $7.35M .
Earnings released on 5 Nov 2020
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $5.88M , beating expectations by +202.80%.
OCUL Stock Performance
Access detailed OCUL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.